We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form

By LabMedica International staff writers
Posted on 02 Oct 2023

The adaptive immune system is an incredible defense mechanism that allows the human body to identify and mount targeted responses against specific pathogens. More...

T-Cells, a special kind of white blood cell, are crucial for directing these immune reactions. These cells have specialized structures called T-Cell receptors that enable them to spot and bind to antigens on infected or abnormal cells. Evaluating T-Cells could offer a more precise understanding of immunity because the immune response from T-Cells generally endures longer than that from antibodies. Now, a new test intended to detect the body’s adaptive immune response to viruses can help respond to future viral threats.

Virax Biolabs (London, UK) is developing the ViraxImmune test, which is designed to measure T-Cell activation when a blood sample encounters a set of proteins simulating viral exposure in the body. Unlike antibodies, T-Cells serve as coordinators of the immune system's fight against viral invasion. Detecting these cells could provide insights into natural resistance against diseases for those who haven't been infected and could also help gauge the level of long-term immunity that someone has after recovering from a viral infection. The ViraxImmune test aims to identify T-Cells that remain in the body long after the initial immune response from antibodies, due to vaccination or infection, has faded. This is expected to offer a more accurate view of long-term immunity compared to just measuring antibody levels.

The ViraxImmune test has additional capabilities. It can identify if someone had been previously exposed to a virus even when initial antibody responses have faded or vanished. It's also possible that someone could have some level of immunity to a virus without ever having been exposed to it. For healthcare providers, the test serves as a sophisticated diagnostic tool that can detect early immune responses, sometimes even before antibodies have a chance to develop. This can enable healthcare providers to make decisions that are tailored to each patient's specific immune characteristics. For individuals being tested, this opens up the possibility of earlier interventions, more closely monitored conditions, and treatment plans that are customized to their needs. The test is structured to fit smoothly into current healthcare workflows, delivering timely and accurate results.

Related Links:
Virax Biolabs 


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.